NasdaqGS:BIIBBiotechs
How Investors Are Reacting To Biogen (BIIB) Advancing Salanersen And Expanding Its SMA Franchise
In early March 2026, Biogen announced new and long-term data from its spinal muscular atrophy programs, including high‑dose nusinersen and the investigational therapy salanersen, alongside updates on biomarker work and global regulatory reviews for an additional dosing option of SPINRAZA.
Separately, Biogen and Stoke Therapeutics reported published clinical results on zorevunersen in Dravet syndrome, highlighting multi‑year seizure reductions and functional gains that support ongoing...